BG101432A - Липозомен състав, съдържащ селегилин - Google Patents

Липозомен състав, съдържащ селегилин

Info

Publication number
BG101432A
BG101432A BG101432A BG10143297A BG101432A BG 101432 A BG101432 A BG 101432A BG 101432 A BG101432 A BG 101432A BG 10143297 A BG10143297 A BG 10143297A BG 101432 A BG101432 A BG 101432A
Authority
BG
Bulgaria
Prior art keywords
composition
salt
disease
selegiline
relates
Prior art date
Application number
BG101432A
Other languages
English (en)
Other versions
BG63327B1 (bg
Inventor
Michael Mezei
Jozsef Gaal
Gabor Szekacs
Gyula Szebeni
Tamasne Marmarosi
Kalman Magyar
Jozsef Lengyel
Istvan Szatmari
Agnes Tueri
Original Assignee
Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. filed Critical Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.
Publication of BG101432A publication Critical patent/BG101432A/bg
Publication of BG63327B1 publication Critical patent/BG63327B1/bg

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Изобретението се отнася до липозомен състав, включващ като активен компонент (-)-N- -диметил-N-(2-пропинил-фенилетиламин) (селегилин) и/или негова сол, който може да се използва за лечение на болест на Алцхаймер, Паркинсонова болест, депресия, мозъчен инсулт, морска болест или миелит. Съдържанието на посочения състав в тегл.% е следния: от 0,1 до 40 селегилин и/или негова сол, от 2 до 40 липиди, за предпочитане фосфолипиди, от 0 до 10 холестерол, от 0 до 20 алкохол, от 0 до 25 гликол, 0-3 антиокислител, 0-3 консервант, 0-2 средство за регулиране на вискозитета, от 0 до 50 циклодекстрин или циклодекстриново производно и от 30 до 90 вода. Изобретението се отнася и до фармацевтичен състав, съдържащ описания липозомен състав при желание заеднос пълнител, разредител или спомагателни вещества,за предпочитане във форма за орално, парентерално или трансдермално приложение, както и до метод за получаване на липозомни състави, съдържащи селегилин и/или негова сол.
BG101432A 1994-10-24 1997-04-22 Липозомен състав, съдържащ селегилин BG63327B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9403073A HU223475B1 (hu) 1994-10-24 1994-10-24 Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
PCT/HU1995/000052 WO1996012472A1 (en) 1994-10-24 1995-10-20 Liposome composition containing selegilin

Publications (2)

Publication Number Publication Date
BG101432A true BG101432A (bg) 1997-12-30
BG63327B1 BG63327B1 (bg) 2001-10-31

Family

ID=10985697

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101432A BG63327B1 (bg) 1994-10-24 1997-04-22 Липозомен състав, съдържащ селегилин

Country Status (30)

Country Link
US (1) US5888536A (bg)
EP (1) EP0788349B1 (bg)
JP (1) JPH10507749A (bg)
KR (1) KR100313149B1 (bg)
CN (1) CN1084186C (bg)
AT (1) ATE205387T1 (bg)
AU (1) AU691348B2 (bg)
BG (1) BG63327B1 (bg)
BR (1) BR9509517A (bg)
CA (1) CA2203513C (bg)
CZ (1) CZ287349B6 (bg)
DE (1) DE69522701T2 (bg)
DK (1) DK0788349T3 (bg)
EE (1) EE03418B1 (bg)
ES (1) ES2160718T3 (bg)
FI (1) FI971743A7 (bg)
HU (1) HU223475B1 (bg)
IL (1) IL115754A (bg)
NO (1) NO316354B1 (bg)
NZ (1) NZ294660A (bg)
PL (1) PL183104B1 (bg)
PT (1) PT788349E (bg)
RO (1) RO116768B1 (bg)
RU (1) RU2159106C2 (bg)
SK (1) SK281599B6 (bg)
TW (1) TW412420B (bg)
UA (1) UA44289C2 (bg)
WO (1) WO1996012472A1 (bg)
YU (1) YU49313B (bg)
ZA (1) ZA958999B (bg)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2319318A1 (en) * 1998-01-27 1999-07-29 Thomas N. Thomas Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl
DE19814257A1 (de) 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
GB9815785D0 (en) * 1998-07-20 1998-09-16 Cerebrus Ltd Chemical compounds
CN1849112B (zh) * 2003-09-09 2012-06-13 吉里德科学公司 治疗性脂质体
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
CN1813679A (zh) * 2005-11-30 2006-08-09 上海医药(集团)有限公司 一种紫杉烷脂质体冻干组合物及其制备方法
US9445975B2 (en) 2008-10-03 2016-09-20 Access Business Group International, Llc Composition and method for preparing stable unilamellar liposomal suspension
JP5693026B2 (ja) * 2010-03-12 2015-04-01 株式会社フジモト・コーポレーション セレギリン含有貼付製剤
JP5623102B2 (ja) * 2010-03-12 2014-11-12 株式会社フジモト・コーポレーション セレギリン含有貼付製剤
EP2846773A4 (en) 2012-05-10 2015-12-30 Painreform Ltd DEPOT FORMULATIONS OF A LOCAL ANESTHETICS AND METHOD FOR THE MANUFACTURE THEREOF
WO2016051424A1 (en) * 2014-09-29 2016-04-07 Council Of Scientific & Industrial Research A formulation useful for delivery of neuro protecting agent
RS65378B1 (sr) * 2017-03-23 2024-04-30 Lipid Systems Sp Z O O Visokoefikasna inkapsulacija hidrofilnih jedinjenja u unilamelarne lipozome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH588887A5 (bg) * 1974-07-19 1977-06-15 Battelle Memorial Institute
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US4937078A (en) * 1988-08-26 1990-06-26 Mezei Associates Limited Liposomal local anesthetic and analgesic products
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same
HU209605B (en) * 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
FR2713087B1 (fr) * 1993-11-30 1996-02-23 Saurat Jean Hilaire Utilisation de la sélégiline et ses dérivés pour la préparation d'un médicament destiné au traitement du psoriasis.

Also Published As

Publication number Publication date
NZ294660A (en) 1998-05-27
SK51797A3 (en) 1997-11-05
PT788349E (pt) 2001-12-28
YU49313B (sh) 2005-06-10
KR100313149B1 (ko) 2002-02-19
NO971870D0 (no) 1997-04-23
HU9403073D0 (en) 1994-12-28
MX9703019A (es) 1997-10-31
EP0788349B1 (en) 2001-09-12
DK0788349T3 (da) 2001-11-26
IL115754A (en) 1999-07-14
NO316354B1 (no) 2004-01-19
AU3751895A (en) 1996-05-15
FI971743L (fi) 1997-04-23
BR9509517A (pt) 1997-12-30
CN1163563A (zh) 1997-10-29
IL115754A0 (en) 1996-01-19
FI971743A0 (fi) 1997-04-23
HUT76053A (en) 1997-06-30
JPH10507749A (ja) 1998-07-28
TW412420B (en) 2000-11-21
SK281599B6 (sk) 2001-05-10
ES2160718T3 (es) 2001-11-16
KR970706797A (ko) 1997-12-01
RU2159106C2 (ru) 2000-11-20
CZ114797A3 (en) 1997-10-15
RO116768B1 (ro) 2001-06-29
CA2203513A1 (en) 1996-05-02
BG63327B1 (bg) 2001-10-31
ATE205387T1 (de) 2001-09-15
DE69522701D1 (de) 2001-10-18
US5888536A (en) 1999-03-30
CA2203513C (en) 2001-10-09
CZ287349B6 (en) 2000-10-11
EE03418B1 (et) 2001-06-15
UA44289C2 (uk) 2002-02-15
YU67195A (sh) 1998-07-10
PL183104B1 (pl) 2002-05-31
PL319875A1 (en) 1997-09-01
WO1996012472A1 (en) 1996-05-02
CN1084186C (zh) 2002-05-08
ZA958999B (en) 1996-05-15
NO971870L (no) 1997-06-24
FI971743A7 (fi) 1997-04-23
HU223475B1 (hu) 2004-07-28
EE9700102A (et) 1997-10-15
DE69522701T2 (de) 2002-07-11
AU691348B2 (en) 1998-05-14
EP0788349A1 (en) 1997-08-13

Similar Documents

Publication Publication Date Title
BG101432A (bg) Липозомен състав, съдържащ селегилин
CA2094267A1 (fr) Utilisation de compositions a base d'alcools gras, pour la preparation d'emulsions; procede de preparation d'emulsions et emulsions ainsi obtenues
BR9711797A (pt) Composição oral, método para preparaçào da composição oral, método para retardar a cárie dentária e artigo manufaturado.
BR9906920A (pt) "tts contendo um antioxidante"
ATE213418T1 (de) Zinc, kupferverbindung und aminosäure enthaltende zusammensetzung zur oralen verabreichung
MY125414A (en) Aminopropylphosphinic acids
LV12766A (lv) Composition of l-dopa esters
DK0699068T3 (da) Reduktion af liposominducerede fysiologiske bivirkninger
PT79648B (de) Verfahren zur herstellung von pharmazeutischen zubereitungen mit speziellen 1,2-diacyl-glycero-3-phosphocholinen zur behandlung von erkrankungen im magen-darm-bereich
CA2140361A1 (en) Composition and methods for decreasing muscle breakdown
TR200002078T2 (tr) Sentetik polisakkaridler, hazırlanmaları için proses ve bunları içeren farmasötik kompozisyonlar.
ATE184788T1 (de) Idebenone-haltige zusammensetzungen zur behandlung von m. alzheimer
AU666426B2 (en) Odorant compositions
ATE160938T1 (de) Feste orale pharmazeutische zubereitung mit gemfibrozil als aktiver inhaltsstoff und verfahren zur herstellung
WO1990012577A3 (en) Topical anti-angiogenic as hair growth inhibitors
EP0558721B1 (en) Odorant compositions
IE890537L (en) Pharmaceutical composition for the transdermal application of heparin
WO2004039335A3 (en) Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
JPH0128725B2 (bg)
JP2012046494A (ja) 内服液剤